3DBiopsy, Inc. is a medical device company that is developing a comprehensive System ultimately intended to aid in the diagnosis and treatment planning of prostate cancer—the most commonly diagnosed significant male cancer and second leading cause of cancer deaths. Created by prostate cancer specialists, the 3DBiopsy System is expected to achieve improvements in biopsy accuracy which may reduce the need for radical surgery or full radiation and lower costs for the healthcare industry.


Chad Hartle

Interim CEO

  • Bio information coming soon…

Brad J. Buscher

Chairman of the Board – Emeritus

  • Mr. Buscher is a merchant banker and through his business has led the financing of the Company to date.
  • He is responsible for the Company’s current product development, product engineering, FDA clearance, IP protection strategy and establishing the Company’s reimbursement strategy.
  • Mr. Buscher has extensive experience with start-up investments in healthcare, medical diagnostics, inorganic chemistry and real estate and has been the Chairman of commercial banks, insurance brokerages, real estate development entities, leasing companies and has extensive experience in the formation and development of early stage enterprises.

Todd Anderson

Chief Financial Officer

  • Mr. Anderson has worked with Mr. Buscher for almost 20 years setting up and growing early-stage companies.
  • He brings his extensive background in setting up systems and controls for start-up entities to the initial phase of financing and operational functions of 3DBiopsy.

Dr. Nelson Stone

Chief Medical Officer and Founder

  • Dr. Stone is Professor of Urology and Radiation Oncology at the Icahn School of Medicine at Mt Sinai, NYC and has authored over 400 articles, abstracts and book chapters and recently  co-authored a new book on localized prostate cancer entitled “The Prostate Cancer Dilemma:  To Treat or Observe, Impact of Genetic Markers, Mapping and mpMRI.”
  • In 1995, Dr. Stone created the 3D Brachytherapy System, PROSEED which was sold to CR Bard in 1998 for $84M.
  • In 2005, Dr. Stone started Prologics, a prostate cancer radiation ablation therapy company that was successfully sold to Integrated Oncology Network in 2011 for a $10 million valuation.

Dr. E. David Crawford

Chief Scientific Officer and Founder

  • Dr. Crawford is an internationally renowned urologist, Endowed Professor of Surgery, Urology and Radiation Oncology.
  • He is Head of the Section of Urologic Oncology at the CU Denver Health Sciences Center and School of Medicine.

Jos J. Groeskamp

Vice President, International Sales and Marketing

  • Mr. Groeskamp will lead the Company’s marketing and sales efforts in the EU, Middle East and Africa.
  • He brings 40 years of experience in urology/radiology sales with CR Bard, QLRAD and Galil Medical.

Dr. Marshall Lucia

Co-Founder, leads the development of the 3D pathology software

  • Dr. Lucia is Professor of Pathology and Vice Chair of Anatomic Pathology at the CU Denver Health Sciences Center and School of Medicine.
  • He has over 20 years of experience in translational biopsy research and 12 years of experience in bio-repository.

Jim Rosa

VP, Regulatory and Quality Assurance

  • Mr. Rosa will lead the Company’s regulatory compliance and quality systems initiatives.
  • He has 35 years of experience in advanced R&D, and Quality Assurance and Regulatory Affairs within regulated industries, primarily medical device, within the U.S. and Europe as well as support to Asia.
*Investigational device. Not available for sale.

Investor Inquiries Welcome.


Call us at 1-800-290-6186, or email us

Chad Hartle
Interim CEO
Cell: 573-576-5433

Brad J. Buscher
Chairman of the Board – Emeritus
Cell: 612-859-2551

Todd J. Anderson
Chief Financial Officer
Cell: 612-839-2457

Nelson N. Stone, MD
Chief MedicalOfficer and Founder
Cell: 845-323-1727

E. David Crawford, MD
Chief Scientific Officer and Founder
Cell: 303-315-5937

Jos J. Groeskamp
Vice President, International Sales and Marketing
Cell: 316-468-5937